azathioprine has been researched along with Central Nervous System Lupus in 10 studies
Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)
azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report a case of neuropsychiatric systemic lupus erythematosus successfully treated with mycophenolate mofetil (MMF)." | 1.42 | Successful Treatment of Lupus Cerebrovascular Disease with Mycophenolate Mofetil. ( Akashi, K; Higashioka, K; Kamada, K; Mizuki, S; Oryoji, K; Tsukamoto, H; Yokota, E; Yoshida, K, 2015) |
| "Even with proper immunosuppressive treatment, SLE can relapse." | 1.37 | Lupus relapse presented as frosted branch retinal angiitis: case report. ( Arellanes-Garcia, L; Cornejo-Ballesteros, H; Hernandez-Da Mota, SE; Melgoza-del-Angel, C; Recillas-Gispert, C; Sanchez-Gonzalez, R; Teran-Estrada, L, 2011) |
| "Maintenance therapy of severe pediatric systemic lupus erythematosus (SLE) usually consists of azathioprine and prednisone ." | 1.35 | Experience with mycophenolate mofetil as maintenance therapy in five pediatric patients with severe systemic lupus erythematosus. ( Amann, K; Benz, K; Dittrich, K; Dötsch, J; Ross, S, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fanouriakis, A | 1 |
| Tziolos, N | 1 |
| Bertsias, G | 1 |
| Boumpas, DT | 1 |
| Papachristos, DA | 1 |
| Oon, S | 1 |
| Hanly, JG | 1 |
| Nikpour, M | 1 |
| Higashioka, K | 1 |
| Yoshida, K | 1 |
| Oryoji, K | 1 |
| Kamada, K | 1 |
| Mizuki, S | 1 |
| Tsukamoto, H | 1 |
| Yokota, E | 1 |
| Akashi, K | 1 |
| Dittrich, K | 1 |
| Ross, S | 1 |
| Benz, K | 1 |
| Amann, K | 1 |
| Dötsch, J | 1 |
| Hernandez-Da Mota, SE | 1 |
| Arellanes-Garcia, L | 1 |
| Recillas-Gispert, C | 1 |
| Cornejo-Ballesteros, H | 1 |
| Melgoza-del-Angel, C | 1 |
| Teran-Estrada, L | 1 |
| Sanchez-Gonzalez, R | 1 |
| Ferraria, N | 1 |
| Rocha, S | 1 |
| Fernandes, VS | 1 |
| Correia, T | 1 |
| Gonçalves, E | 1 |
| Harten, P | 1 |
| Kato, T | 1 |
| Shiratori, K | 1 |
| Kobashigawa, T | 1 |
| Hidaka, Y | 1 |
| Everett, CM | 1 |
| Graves, TD | 1 |
| Lad, S | 1 |
| Jäger, HR | 1 |
| Thom, M | 1 |
| Isenberg, DA | 1 |
| Hanna, MG | 1 |
| Gibbs, AN | 1 |
| Moroney, J | 1 |
| Foley-Nolan, D | 1 |
| O'Connell, PG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Optimization of Glucocorticoid Taper Strategies for Maintenance Therapy of Systemic Lupus Erythematosus Associated Immune Thrombocytopenia (SLE-ITP)[NCT05506033] | 120 participants (Anticipated) | Interventional | 2022-08-15 | Enrolling by invitation | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for azathioprine and Central Nervous System Lupus
| Article | Year |
|---|---|
Update οn the diagnosis and management of systemic lupus erythematosus.
Topics: Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Humanized; Autoantibodies; Azathioprine; Calc | 2021 |
Management of inflammatory neurologic and psychiatric manifestations of systemic lupus erythematosus: A systematic review.
Topics: Azathioprine; Cyclophosphamide; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Lup | 2021 |
8 other studies available for azathioprine and Central Nervous System Lupus
| Article | Year |
|---|---|
Successful Treatment of Lupus Cerebrovascular Disease with Mycophenolate Mofetil.
Topics: Adult; Azathioprine; Female; Humans; Immunosuppressive Agents; Interleukin-6; Ischemic Attack, Trans | 2015 |
Experience with mycophenolate mofetil as maintenance therapy in five pediatric patients with severe systemic lupus erythematosus.
Topics: Adolescent; Azathioprine; Child; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy | 2009 |
Lupus relapse presented as frosted branch retinal angiitis: case report.
Topics: Adolescent; Azathioprine; Female; Humans; Immunosuppressive Agents; Lupus Vasculitis, Central Nervou | 2011 |
Juvenile systemic lupus erythematosus with primary neuropsychiatric presentation.
Topics: Anti-Inflammatory Agents; Antibodies, Antinuclear; Ataxia; Azathioprine; Child; Cognition Disorders; | 2013 |
[Drug alternatives in therapy of neuropsychiatric systemic lupus erythematosus (NPSLE)].
Topics: Antibodies, Antiphospholipid; Anticoagulants; Antirheumatic Agents; Azathioprine; Coumarins; Cycloph | 2003 |
Systemic lupus erythematosus with organic brain syndrome: serial electroencephalograms accurately evaluate therapeutic efficacy.
Topics: Azathioprine; Cerebrospinal Fluid; Cyclophosphamide; Disorders of Excessive Somnolence; Electroencep | 2006 |
Aggressive CNS lupus vasculitis in the absence of systemic disease activity.
Topics: Anticonvulsants; Autoantibodies; Azathioprine; Brain; Cyclophosphamide; Electroencephalography; Fema | 2008 |
Neuromyelitis optica (Devic's syndrome) in systemic lupus erythematosus: a case report.
Topics: Anti-Inflammatory Agents; Azathioprine; Drug Therapy, Combination; Female; Humans; Immunosuppressive | 2002 |